Neurotransmitters act as chemical messengers that are released from neurons in order to communicate with other cells. These neurotransmitters can activate several signaling pathways within the body that ultimately lead to a variety of cellular responses. Essentially, the release of neurotransmitters serves as an intercellular communication mechanism between neurons and other cells. Neurons produce several types of neurotransmitters, all of which can act on cell surface receptors that are specific to a particular type of neurotransmitter. Once the receptor detects a neurotransmitter, it triggers a chain of events inside the cell known as signal transduction, which involves relaying the message from the neurotransmitter to the target cell. Some of the most widely studied neurotransmitters include acetylcholine, norepinephrine, serotonin and dopamine. Signaling can be thought of as a highly-orchestrated collaboration between neurons and other cells in order to relay information within the body. For example, when dopamine is released from a neuron it binds to specific receptors on the surface of another cell that then activates other mechanisms within the cell that can alter the cell’s behavior. This communication network is essential for normal physiological function, especially in the brain and the nervous system. The neurotransmitters and their respective receptors are exquisitely regulated, and the existence of defects in neurotransmitter systems can lead to numerous medical conditions, such as depression, Parkinson’s disease, and Alzheimer’s disease. Many drugs on the market today are designed to target specific neurotransmitters, such as selective serotonin re-uptake inhibitors (SSRI), which are commonly used to treat depression. By understanding the physiological mechanisms surrounding neurotransmitter release, scientists can continue to uncover new treatments for neuropsychiatric disorders.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States